Navigation Links
Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
Date:3/30/2009

government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

GlaxoSmithKline

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit http://www.gsk.com

    For further information please contact:

    Investor Relations Clea Rosenfeld (Rest of the World) +44-1256-894-160
                       Eric Rojas (North America)         +1-617-551-9715
    Media              Jessica Mann (Rest of the World)   +44-1256-894-280
                       Matthew Cabrey (Specialty Pharma)  +1-484-595-8248



'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Publication of Shire plcs Annual Report 2008
2. Shires Project Playground Gives Boost to Philadelphia
3. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
4. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
5. Shire Announces Opening of Office in Japan
6. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
7. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
8. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
9. Shire plc: Change to Directors Details
10. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
11. Shires New Product Portfolio Delivers Strong Quarterly Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 Seventh Wave Laboratories, ... and efficacy of pharmaceutical products and medical devices, announced ... MO 63043, a 50,000 sq. ft. building more than ... enable strategic growth. Facility renovations will begin immediately and ... space will occur in September. , “We are ...
(Date:5/21/2015)... 2015  Prima Biomed Ltd. (NASDAQ: PBMD ) ... become a leader in the development of immunotherapeutic products ... final CVac data from the Phase II CAN-003 ovarian ... a clinically meaningful improvement in Overall Survival ("OS") over ... In the group of second remission patients (n=20), ...
(Date:5/21/2015)... , May 21, 2015 Imagine ... feelings - and those of others. Being able to ... Analyze and read people to anticipate their thoughts and ... deepest emotions and feelings to create unique abstract paintings ... responsive games. Get inside a first-person-shooter as it creates ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation ... development company specializing in oncology, today announced positive ... trial with aldoxorubicin for the treatment of unresectable ... cancer.  The open-label, multisite trial is designed to ... in patients whose tumors have progressed following prior ...
Breaking Biology Technology:Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... 12, 2009 NEW YORK, March 5 Keryx Biopharmaceuticals, ... it received a letter from the Staff of The ... to regain compliance with Nasdaq Marketplace Rule 4310(c)(3), which ... in stockholders, equity, or $35,000,000 market value of listed ...
... Inc., announced today that it has successfully completed a ... Capital on behalf of the MPM Bio IV NVS ... of a Phase 1/2 human clinical study of its ... disease undergoing surgery for arteriovenous fistula (AVF) creation. Additionally, ...
... revolutionary Trusted LASIK Surgeons directory service and website at ... for consumers seeking to improve their vision and find ... chances of attaining 20-20 vision. What sets the ... process ensuring that only those who are among the ...
Cached Biology Technology:Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 2Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 3Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 4Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 2Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 3Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 4Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 5Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 6Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 7
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... WASHINGTON, Aug. 17--Researchers are able to achieve extremely ... depletion (STED) microscopy. This cutting-edge imaging system has pushed ... enabling them to image features that are even smaller ... They are able to achieve this extreme vision by ...
... Five days after the Twin Towers collapsed, two geoscientists ... were part of a team that would use remote sensing ... workers, civilians and survivors of the terrorist attacks. One of ... A second was to create a compositional profile of the ...
... have developed a simple, scalable way to align gold ... for emerging biomedical imaging technologies. Aligning gold nanorods ... on the direction in which the nanorods are pointed. ... want to ensure that all of the nanorods are ...
Cached Biology News:Researchers find way to align gold nanorods on a large scale 2
SH3 Proteins II Sampler Kit 10g each...
Tumor Suppressor Sampler Kit 10 mu g each...
Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Biology Products: